WEBULL
WebtradeDownload

Medtronic (MDT), Why Is Its Latest Update Drawing Attention?

Simply Wall St · 1d ago

Medtronic (MDT) is back in the headlines after the U.S. Food and Drug Administration cleared its LigaSure RAS Maryland jaw device for use with the Hugo robotic-assisted surgery system.

For investors tracking the bigger picture, Medtronic’s 1-year total shareholder return is down 2.8%, even though the 3-year total shareholder return is up 24.8%. At the same time, the 90-day share price return of 9.5% points to momentum building around recent product wins, partnerships, and its steady dividend profile.

Spot opportunities around Medtronic’s robotics and surgery story by scanning a curated set of 92 robotics and automation stocks that could be setting up their next move.

Medtronic’s recent pop on robotics and partnerships raises a simple fork-in-the-road question. Is this just the market catching up to fair value, or is pricing still lagging what the current numbers suggest the business is worth?

Most Popular Narrative: 23.2% Undervalued

Medtronic last closed at $88.64, while the most followed narrative pegs fair value at $115.38. This frames a sizable valuation gap that investors are trying to explain through the recent operating story.

Medtronic's fiscal first quarter of 2027 arrived with 13.7% organic growth, a number that would be arresting in any quarter. This figure was inflated by an extra selling week that management estimates contributed roughly 670 basis points. If the calendar effect is removed, the underlying figure still represents, by their own account, the strongest performance in nearly eight years.

See why 5 investors see Medtronic as 23% undervalued.

Result: Fair Value of $115.38 (UNDERVALUED)

Still, Medtronic’s story can crack if robotics uptake stalls or if the MiniMed separation takes longer than investors now expect and muddies the margin picture.

Find out about the key risks to this Medtronic narrative.

Next Steps

Sentiment in this piece leans positive on Medtronic. Move quickly, test that optimism against your own criteria, and then pressure test the upside by checking the 5 key rewards.

Looking for more Medtronic-sized investment ideas?

Do not stop with Medtronic. Use the Simply Wall Street Screener to quickly surface fresh ideas that match the kind of edge you want in your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.